Table 1.
Cohort Characteristics
| MLE (n = 36) | No MLE (n = 139) | P Value | |
|---|---|---|---|
| Median age (y) | 64 (55–77) | 59 (42–74) | <.001 |
| Median BMIa (kg/m2) | 27.3 (21.7–37.9) | 27.2 (19.4–37.6) | .62 |
| Median ASAa score | 2 (2–3) | 2 (1–4) | .94 |
| Median PSAa (ng/mL) | 6.0 (1.7–13.2) | 5.4 (1.1–37.2) | .40 |
| No. receiving α-blocker and/or 5-ALPHA REDUCTASE INHIBITOR | 13 (36%) | 8 (6%) | <.0001 |
| No. with Gleason score of 6 | 24 (67%) | 64 (46%) | .04 |
| Median prostate weight (g) | 62 (27–125) | 47 (20–103) | <.001 |
| Median surgery time (min) | 256 (206–377) | 249 (185–358) | .37 |
| No. with bladder neck contracture | 0 | 4 (3%) | .58 |
| No. with stage pT3x | 3 (8%) | 30 (22%) | .09 |
| No. with positive surgical margin | 3 (8%) | 25 (18%) | .20 |
a
ASA = American Society of Anesthesiologists; BMI = body mass index; PSA = prostate-specific antigen.